lapatinib / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

70 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
NCT00169533: Rollover Study Of Lapatinib In Cancer Patients

Completed
1b
31
US, Canada, RoW
GW572016 oral tablets
GlaxoSmithKline
Neoplasms, Breast
05/09
05/09
NCT01281163: Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Terminated
1b
4
US
Akt Inhibitor MK2206, MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
12/13
12/13
NCT00085020: GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Completed
1
13
US
trastuzumab, lapatinib ditosylate
Jonsson Comprehensive Cancer Center, GlaxoSmithKline
Breast Cancer
12/04
02/05
NCT00148902: Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Completed
1
52
US
lapatinib, docetaxel
GlaxoSmithKline
Neoplasms, Breast
01/06
01/06
NCT00295243: Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

Completed
1
25
US
Topotecan
Mayo Clinic, GlaxoSmithKline
Advanced Solid Malignancies
 
11/06
NCT00331630: Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Checkmark Clinical data - SABCS
Dec 2012 - Dec 2012: Clinical data - SABCS
Completed
1
30
US
lapatinib ditosylate, Tykerb, Tyverb, paclitaxel albumin-stabilized nanoparticle formulation, Abraxane, ABI-007
Northwestern University, GlaxoSmithKline, Celgene Corporation
Breast Cancer
11/06
08/10
NCT00258050: To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Completed
1
24
US
Midazolam, GW572016 oral tablets, Lapatinib
GlaxoSmithKline
Neoplasms, Breast
02/07
02/07
NCT00317434: Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Terminated
1
12
US
lapatinib
University of Alabama at Birmingham, GlaxoSmithKline
Ovarian Cancer
03/07
04/07
NCT00352443: S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Checkmark Combination of lapatinib & everolimus in advanced cancer
Sep 2013 - Sep 2013: Combination of lapatinib & everolimus in advanced cancer
Completed
1
66
US
everolimus, lapatinib ditosylate
Southwest Oncology Group, National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
08/07
09/13
NCT00158782: Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Completed
1
75
US, Europe
GW786034, lapatinib
GlaxoSmithKline
Carcinoma, Renal Cell
08/07
08/07
BrUOG-PA205, NCT00439179: A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

Completed
1
27
US
cohort 1, cohort 2, cohort 3, cohort 4
Brown University, GlaxoSmithKline
Metastatic Pancreatic Cancer
12/07
12/07
NCT00371488: GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Completed
1
11
Japan
GW572016 oral tablets
GlaxoSmithKline
Neoplasms, Breast
12/07
12/07
NCT00359190: Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Completed
1
28
US, RoW
lapatinib
GlaxoSmithKline
Neoplasms, Breast
01/08
01/08
NCT00513253: A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

Withdrawn
1
0
US
lapatinib
GlaxoSmithKline
Healthy Subjects
05/08
05/08
BrUOG-PA-209, NCT00447122: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

Terminated
1
25
US
Gemcitabine 1000mg/m2 30 minutes, Gemzar, Lapatinib 1000mg/d, Tykerb, Tyverb, Lapatinib 1500mg/d, Gemcitabine 1000mg/m2 100minutes, Oxaliplatin 100mg/m2, Eloxatin
Brown University, Rhode Island Hospital, The Miriam Hospital, Memorial Hospital of Rhode Island
Metastatic Pancreatic Cancer
08/08
08/08
NCT00753207: Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

Completed
1
10
Europe
epirubicin hydrochloride, lapatinib ditosylate, biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry
Cancer Trials Ireland
Breast Cancer
11/08
03/12
NCT00632489: LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Completed
1
20
US
LBH589, Panobinostat, Capecitabine, Xeloda, Lapatinib, Tykerb, Tyverb
SCRI Development Innovations, LLC, Novartis
Breast Cancer
01/09
07/11
NCT00389922: Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

Completed
1
22
US
lapatinib ditosylate, Tykerb, vinorelbine ditartrate, Navelbine, comparative genomic hybridization, cytogenetic analysis, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis, Vinorelbine ditartrate
University of California, Davis, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
04/09
12/11
LAPATAM, NCT00424164: Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer

Checkmark Lapatinib & tamoxifen in mBC
Jul 2014 - Jul 2014: Lapatinib & tamoxifen in mBC
Completed
1
20
Europe
lapatinib ditosylate, tamoxifen citrate, pharmacological study
European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
06/09
05/10
NCT00650910: Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Completed
1
17
US, Canada, RoW
lapatinib, Digoxin
GlaxoSmithKline
Neoplasms, Breast
07/09
07/09
NCT00388076: Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Completed
1
86
US
Pazopanib, Lapatinib, paclitaxel, TAXOL, carboplatin, PARAPLATIN
GlaxoSmithKline
Neoplasms, Breast
07/09
07/09
NCT00849329: A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Completed
1
12
US, Europe, RoW
lapatinib, lapatinib plus esomeprazole
GlaxoSmithKline
Neoplasms, Breast
11/09
11/09
NCT00470847: Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Completed
1
35
US
Lapatinib, Tykerb, Whole Brain Radiation, Herceptin, Trastuzumab
Nancy Lin, MD, Brigham and Women's Hospital, Breast Cancer Research Foundation, GlaxoSmithKline
Breast Cancer, Brain Metastases
12/09
06/12
NCT00513058: Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Completed
1
33
Europe
Lapatinib, TYVERB, vinorelbine, NAVELBINE
UNICANCER
Breast Cancer
05/10
04/12
NCT00379509: Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Completed
1
20
US
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Breast Cancer
06/10
08/12
NCT00634088: Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Terminated
1
13
US, Europe, RoW
Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone + Lapatinib + Capecitabine
R-Pharm, GlaxoSmithKline
Locally Advanced or Metastatic Breast Cancer
06/10
06/10
PGT, NCT01133912: Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®)

Completed
1
13
RoW
paclitaxel, gemcitabine, lapatinib, Paclitaxel, Gemzar, Tykerb
Jungsil Ro, GlaxoSmithKline, HK inno.N Corporation
Breast Cancer
06/10
10/11
NCT00516672: Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Completed
1
30
Japan
pazopanib, Lapatinib
GlaxoSmithKline
Carcinoma, Renal Cell
08/10
10/15
NCT00367471: Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Completed
1
31
US
lapatinib, carboplatin, trastuzumab, paclitaxel
Novartis Pharmaceuticals
Neoplasms, Breast
12/10
09/19
NCT00682279: A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

Withdrawn
1
0
US
oral topotecan (SK&F-104864); lapatinib (GW572016)
GlaxoSmithKline
Advanced Solid Tumors
03/11
03/11
NCT00821054: A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Completed
1
24
US, Canada, Europe
Lapatinib, TYKERB - US; TYVERB - UK
GlaxoSmithKline
Neoplasms, Breast
03/11
03/11
LAPTEM, NCT00614978: Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

Checkmark ESMO 2013
Sep 2013 - Sep 2013: ESMO 2013
Completed
1
18
Europe
lapatinib and temozolomide, Tykerb
Jules Bordet Institute, GlaxoSmithKline, Schering-Plough
Metastatic Breast Cancer, Brain Metastases, HER2 Positive
06/11
06/11
NCT00316875: Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Checkmark P1 data - ASCO
Jun 2012 - Jun 2012: P1 data - ASCO
Completed
1
23
US
lapatinib ditosylate, Doxil, Doxorubicin HCL Liposome Injection, Dox-SL
Northwestern University, National Cancer Institute (NCI)
Breast Cancer
08/11
08/11
UCDCC#207, NCT00804310: Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors

Terminated
1
5
US
ixabepilone, Ixempra, lapatinib ditosylate, Tykerb/Tyverb
University of California, Davis, National Cancer Institute (NCI), Genentech, Inc., Bristol-Myers Squibb
Unspecified Adult Solid Tumor, Protocol Specific
08/11
09/11
MK-2206-015, NCT00963547: A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors

Checkmark In combination with trastuzumab in pts with HER2-positive solid tumors
Nov 2013 - Nov 2013: In combination with trastuzumab in pts with HER2-positive solid tumors
Checkmark P1 data
Jun 2011 - Jun 2011: P1 data
Terminated
1
33
NA
MK-2206, Trastuzumab, Lapatinib
Merck Sharp & Dohme LLC
Advanced Solid Tumors, Breast Cancer
08/11
12/11
LAPAINBLAD, NCT01245660 / 2009-012714-49: A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

Terminated
1
3
Europe
LAPATINIB
University Hospital, Bordeaux
Bladder Carcinoma, Infiltrative Bladder Carcinoma, Cystectomy
10/11
10/11
NCT00623064: Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Completed
1
18
Europe
cisplatin, gemcitabine hydrochloride, lapatinib ditosylate, pharmacological study
European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
06/12
08/12
NCT01471847 / 2011-003602-25: A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Checkmark P1 data - ASCO
Jun 2012 - Jun 2012: P1 data - ASCO
Completed
1
5
Europe
BEZ235 + Trastuzumab Phase l/Phase ll), Lapatinib + Capecitabine (Phase II)
Novartis Pharmaceuticals
Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)
06/12
06/12
NCT00984425: The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

Checkmark P1 data
Nov 2012 - Nov 2012: P1 data
Completed
1
30
Europe
Lapatinib and Sorafenib, Tykerb and Nexavar
Istituto Clinico Humanitas
Solid Tumors
07/12
08/13
NCT00996762: A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Completed
1
158
US, RoW
lapatinib, 1250 mg alternative formulation 1, 1250 mg alternative formulation 3, 1250 mg alternative formulation 2
GlaxoSmithKline
Neoplasms, Breast
09/12
09/12
NCT00495872: Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Completed
1
204
US
Dasatinib, Sprycel®, BMS-354825, Erlotinib, Erlotinib Hydrochloride, OSI-774, Tarceva, Lapatinib, GW572016, Lenalidomide, CC-5013, Revlimid™, Sorafenib, BAY 43-9006, Sunitinib, Sunitinib Malate, SU011248, Valproic Acid, Depakene
M.D. Anderson Cancer Center
Solid Tumors
10/12
 
NCT01199367: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Terminated
1
11
US
KW-2450 in combination with lapatinib and letrozole, KW-2450 lapatinib and letrozole
Kyowa Kirin Co., Ltd., Kyowa Hakko Kirin Pharma, Inc.
Breast Cancer
12/12
12/12
NCT01290354: Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
10
Europe
Lapatinib, Tykerb, Tyverb, [11C] lapatinib
GlaxoSmithKline
Cancer
03/13
03/13
NCT01454479: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Unknown status
1
24
NA
Lapatinib and ixempra, Lapatinib, Ixempra
Hung-Hsueh Chou, GlaxoSmithKline, Bristol-Myers Squibb
Recurrent Endometrial Cancer
04/13
04/14
NCT01705340: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Terminated
1
60
US
Akt inhibitor MK2206, MK2206, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
05/13
 
NCT00544804: Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Completed
1
41
US
lapatinib ditosylate, gene expression analysis, diagnostic laboratory biomarker analysis
University of California, San Francisco, National Cancer Institute (NCI)
Breast Cancer, Metastatic Cancer
06/13
12/13
TYKERB-ITUX 1, NCT01184482: Lapatinib and Cetuximab in Patients With Solid Tumors

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1 data
May 2012 - May 2012: P1 data
Completed
1
22
US
cetuximab and lapatinib, Cetuximab: erbitux, Lapatinib: tykerb
Georgetown University, GlaxoSmithKline
Colorectal Cancer, Lung Cancer, Head and Neck Cancer
06/13
09/13
NCT00313599: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed
1
28
US
lapatinib, Tykerb, Tyverb, lapatinib ditosylate, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, Abraxane, Taxol
University of California, San Francisco, National Cancer Institute (NCI)
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
12/13
12/13
NCT00807859: Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P1 data - ASCO
Jun 2012 - Jun 2012: P1 data - ASCO
Completed
1
65
Europe, US
AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab, AMG 386 10 mg/kg, Capecitabine and Lapatinib
Amgen
Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
02/14
10/15
NCT01304784: A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Checkmark Presentation of biomarker data for advanced HER2 positive solid tumors at ESMO 2014
Sep 2014 - Sep 2014: Presentation of biomarker data for advanced HER2 positive solid tumors at ESMO 2014
Checkmark Presentation of data for advanced HER2 positive solid tumors (tumor type not specified) at ASCO 2014
May 2014 - Jun 2014: Presentation of data for advanced HER2 positive solid tumors (tumor type not specified) at ASCO 2014
Checkmark Multiple combination regimens (ESMO 2012)
More
Completed
1
100
US
Cisplatin, Capecitabine, Trastuzumab and MM-111, Capecitabine = Xeloda, Trastuzumab = Herceptin, Lapatinib +/- Trastuzumab and MM-111, Lapatinib = Tykerb, Paclitaxel, Trastuzumab and MM-111, Paclitaxel = Taxol, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111, Docetaxel = Taxotere
Merrimack Pharmaceuticals
HER-2 Gene Amplification
04/14
06/14
CELAVIE, NCT01238029 / 2009-017219-13: Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Terminated
1
12
Europe
Lapatinib and Capecitabine and Vinorelbine, Xeloda, Tyverb, Navirel
Sponsor GmbH, iOMEDICO AG, Arbeitsgemeinschaft fur Internistische Onkologie, Arbeitskreis Klinische Studien, GlaxoSmithKline
Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy, Failure or Contraindication of Trastuzumab Therapy
07/14
07/14
NCT00863122: Concentration and Activity of Lapatinib in Vestibular Schwannomas

Completed
1
26
US
lapatinib, Tykerb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Children's Tumor Foundation, GlaxoSmithKline, New York University, Ohio State University, House Research Institute, Washington University School of Medicine, Weill Medical College of Cornell University, Massachusetts General Hospital
Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor
08/14
08/14
NCT01245205: Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
28
US
Akt inhibitor MK2206, MK2206, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
08/14
 
NCT01427322: Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease

Terminated
1
6
US
Lapatinib, GW572016, Tykerb, Radiation therapy
Virginia Commonwealth University
Epithelial Cancer
12/14
07/15
NCT00662636: Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Completed
1
27
US
dasatinib, BMS-354825, Sprycel, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, pharmacological study, pharmacological studies, laboratory biomarker analysis
Mayo Clinic, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
12/14
12/14
NCT01454804: Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Completed
1
43
US
Pazopanib, GW78634, Lapatinib, Tykerb, GW572016, Trastuzumab (Herceptin®), Herceptin
M.D. Anderson Cancer Center
Advanced Cancers
03/15
03/15
NCT01087983: Lapatinib With Sirolimus or Metformin

Completed
1
111
US
Lapatinib, Tykerb, GW572016, Sirolimus, Rapamune, Metformin, Glucophage
M.D. Anderson Cancer Center
Advanced Cancers
09/15
09/15
NCT01497626: Lapatinib and Bortezomib in Patients With Advanced Malignancies

Terminated
1
15
US
Lapatinib and bortezomib, Velcade
Georgetown University, GlaxoSmithKline, Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors
12/15
12/15
NCT02131506: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

Terminated
1
11
Europe
Lapatinib, Caelyx, Lapatinib, Caelyx
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
HER-2 Positive Breast Cancer, Malignant Neoplasm of Breast
01/16
01/16
NCT01434303: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Completed
1
37
US
Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS-275, SNDX-275, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Trastuzumab, ABP 980, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, PF-05280014, rhuMAb HER2, RO0452317, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab-dkst
National Cancer Institute (NCI)
HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
02/16
02/16
NCT02581124: Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Completed
1
10
US
JTZ-951, Lapatinib
Akros Pharma Inc.
Anemia of Chronic Kidney Disease
04/16
04/16
NCT00790816: Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Completed
1
500
US, Canada, Europe, RoW
Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Novartis Pharmaceuticals
Neoplasms, Breast
08/16
08/16
NCT01875666: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Completed
1
26
US
Trastuzumab, Herceptin, pertuzumab, Perjeta, lapatinib, Tykerb
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc., Susan G. Komen Breast Cancer Foundation, GlaxoSmithKline
Breast Neoplasms
12/16
12/16
NCT01300962: Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Completed
1
47
US
BMK120, Capecitabine, Xeloda, BYL719, Trastuzumab, Herceptin, Lapatinib, Tykerb
UNC Lineberger Comprehensive Cancer Center, Novartis Pharmaceuticals
Metastatic Breast Cancer
02/17
12/18
STELA, NCT02073916: T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Completed
1
24
US
T-DM1, Trastuzumab Emtansine, TE, Kadcyla, Lapatinib, Tykerb, Abraxane, nab-paclitaxel
Jenny C. Chang, MD, The Methodist Hospital Research Institute
Metastatic Breast Cancer
12/18
12/18
NCT00543504: Bevacizumab in Multiple Phase I Combinations

Checkmark Heavily pretreated HER2+ve BC
Oct 2013 - Oct 2013: Heavily pretreated HER2+ve BC
Completed
1
343
US
Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Sorafenib, BAY 43-9006, Erlotinib, Erlotinib hydrochloride, OSI-774, Tarceva, Trastuzumab, Herceptin, Lapatinib, GW572016, Tykerb, Sunitinib, Sunitinib Malate, SU011248, Sutent, Cetuximab
M.D. Anderson Cancer Center
Advanced Cancer
04/20
04/20
NCT02650752: Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Completed
1
11
US
Lapatinib in Tandem With Capecitabine
Memorial Sloan Kettering Cancer Center, Queens Cancer Center of Queens Hospital, University of Michigan
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
01/21
01/21
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Active, not recruiting
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/25
NCT01947023: Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Active, not recruiting
1
21
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
12/24
12/24
NCT04608409: Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Active, not recruiting
1
15
US
Lapatinib and Paclitaxel
Frederick R. Ueland, M.D., National Cancer Institute (NCI)
Ovarian Cancer
06/25
06/25

Download Options